News | November 25, 2023
DxVx plans to make a license-in agreement of OVM-200
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
The product will be manufactured at Lupin’s Nagpur facility in India
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Subscribe To Our Newsletter & Stay Updated
